ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Vitamin Replacement in Abetalipoproteinemia

This study has been completed.

Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00004574
  Purpose

This study will determine whether short term intravenous infusion of vitamins A and E in patients with abetalipoproteinemia can reverse disease symptoms in these patients. Abetalipoproteinemia is an inherited metabolic defect that prevents fat-soluble vitamins, such as A and E, from being absorbed from the intestines into the bloodstream and from being secreted by the liver. The deficiencies of vitamins A and E can result in severe vision impairment and a gait disorder. Treatment with megadoses of these vitamins, taken by mouth, may delay or arrest symptoms, but many continue to progress.

For this study, a single patient with moderately severe eye and neurological defects will be given essential fatty acids and fat soluble vitamins directly through a vein (intravenously) using FDA-approved replacements with a fat emulsion and multivitamins containing fat-soluble vitamins. This route of administration will bypass the digestive tract, where the absorption problem occurs. The infusions will be given twice a week for one month and then weekly for another month. Blood tests will be done weekly to measure blood lipids (fatty acids and other substances), cell counts, and vitamin levels. Eye and neurological examinations will be done once a month.


Condition
Abetalipoproteinemia

Genetics Home Reference related topics:   abetalipoproteinemia    cholesteryl ester storage disease    Farber lipogranulomatosis    Friedreich ataxia    long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency    mitochondrial trifunctional protein deficiency    primary carnitine deficiency    Tangier disease   

Drug Information available for:   Vitamin E    alpha-Tocopherol    alpha-Tocopheryl acetate    Tocopherols    Vitamin A    Retinol   

U.S. FDA Resources

Study Type:   Observational
Official Title:   Vitamin Replacement in Abetalipoproteinemia

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:   1
Study Start Date:   February 2000
Estimated Study Completion Date:   May 2001

Detailed Description:

Fat-soluble vitamins are normally absorbed from the diet through the gastrointestinal tract and incorporated into fat-rich particles called chylomicrons made in the intestinal wall. Chylomicrons are secreted by the intestine into the bloodstream. In a rare lipid metabolic disorder called abetalipoproteinemia, a defect in the assembly of the fat and vitamin containing particles prevents the formation of chylomicrons resulting in the malabsorption of fat and fat-soluble vitamins. A similar assembly defect of fat and fat-soluble vitamins occurs in the liver and prevents the secretion of these particles. Severe fat-soluble vitamin deficiency results even despite mega doses of oral fat-soluble vitamins. Clinically, the subjects develop neurologic and ophthalmologic symptoms similar to those in Vitamin A and E deficiency. This study is designed to determine whether short-term intravenous fat-soluble vitamins and fat emulsion can reverse the neurologic and ophthalmologic complications of fat-soluble vitamin deficiency based on noninvasive procedures routinely employed in clinical practice.

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

None provided - protocol is intended for one patient only.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004574

Locations
United States, Maryland
National Heart, Lung and Blood Institute (NHLBI)    
      Bethesda, Maryland, United States, 20892

Sponsors and Collaborators
  More Information


Publications:

Study ID Numbers:   000076, 00-H-0076
First Received:   February 17, 2000
Last Updated:   March 3, 2008
ClinicalTrials.gov Identifier:   NCT00004574
Health Authority:   United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Abetalipoproteinemia  
Ataxia  
Retinitis Pigmentosa  
Vitamin A  
Vitamin E  

Study placed in the following topic categories:
Lipid Metabolism, Inborn Errors
Tocopherol acetate
Metabolic Diseases
Retinitis
Hypolipoproteinemia
Hypolipoproteinemias
Alpha-Tocopherol
Abetalipoproteinemia
Tocopherols
Pigmentary retinopathy
Hypobetalipoproteinemias
Metabolism, Inborn Errors
Vitamin E
Retinol palmitate
Genetic Diseases, Inborn
Vitamin A
Retinitis Pigmentosa
Cone rod dystrophy
Ataxia
Metabolic disorder
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers